Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Lewis Rubin

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Anatomy

Chemicals & Drugs

Physiology

Concepts & Ideas

Living Beings

Rats

Procedures

Double-Blind Method

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Badesch David B; McGoon Michael D; Barst Robin J; Tapson Victor F; Rubin Lewis J; Wigley Fredrick M; Kral Kenneth M; Raphiou Ibrahim H; Crater Glenn D
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
Adamali Huzaifa; Gaine Sean P; Rubin Lewis J
Medical treatment of pulmonary arterial hypertension.
Barst Robyn J; Gibbs J Simon R; Ghofrani Hossein A; Hoeper Marius M; McLaughlin Vallerie V; Rubin Lewis J; Sitbon Olivier; Tapson Victor F; Galiè Nazzareno
Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lewis Rubin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Badesch David B; McGoon Michael D; Barst Robin J; Tapson Victor F; Rubin Lewis J; Wigley Fredrick M; Kral Kenneth M; Raphiou Ibrahim H; Crater Glenn D
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
The Journal of rheumatology 2009;36(10):2244-9.
2009: Adamali Huzaifa; Gaine Sean P; Rubin Lewis J
Medical treatment of pulmonary arterial hypertension.
Seminars in respiratory and critical care medicine 2009;30(4):484-92.
2009: Barst Robyn J; Gibbs J Simon R; Ghofrani Hossein A; Hoeper Marius M; McLaughlin Vallerie V; Rubin Lewis J; Sitbon Olivier; Tapson Victor F; Galiè Nazzareno
Updated evidence-based treatment algorithm in pulmonary arterial hypertension.
Journal of the American College of Cardiology 2009;54(1 Suppl):S78-84.
2009: Yao Weijuan; Firth Amy L; Sacks Richard S; Ogawa Aiko; Auger William R; Fedullo Peter F; Madani Michael M; Lin Grace Y; Sakakibara Naohide; Thistlethwaite Patricia A; Jamieson Stuart W; Rubin Lewis J; Yuan Jason X-J
Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension.
American journal of physiology. Lung cellular and molecular physiology 2009;296(6):L870-8.
2009: Yu Ying; Keller Steve H; Remillard Carmelle V; Safrina Olga; Nicholson Ann; Zhang Shenyuan L; Jiang Weihua; Vangala Nivruthi; Landsberg Judd W; Wang Jian-Ying; Thistlethwaite Patricia A; Channick Richard N; Robbins Ivan M; Loyd James E; Ghofrani Hossein A; Grimminger Friedrich; Schermuly Ralph T; Cahalan Michael D; Rubin Lewis J; Yuan Jason X-J
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension.
Circulation 2009;119(17):2313-22.
2009: McGoon Michael D; Frost Adaani E; Oudiz Ronald J; Badesch David B; Galie Nazzareno; Olschewski Horst; McLaughlin Vallerie V; Gerber Michael J; Dufton Chris; Despain Darrin J; Rubin Lewis J
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Chest 2009;135(1):122-9.
2009: Chin Kelly M; Channick Richard N; de Lemos James A; Kim Nick H; Torres Fernando; Rubin Lewis J
Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
Chest 2009;135(1):130-6.
2008: Jaïs Xavier; D'Armini Andrea M; Jansa Pavel; Torbicki Adam; Delcroix Marion; Ghofrani Hossein A; Hoeper Marius M; Lang Irene M; Mayer Eckhard; Pepke-Zaba Joanna; Perchenet Loïc; Morganti Adele; Simonneau Gérald; Rubin Lewis J;
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Journal of the American College of Cardiology 2008;52(25):2127-34.
2008: Oudiz Ronald J; Rubin Lewis J
Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases.
Circulation 2008;118(21):2120-1.
2008: Simonneau Gérald; Rubin Lewis J; Galiè Nazzareno; Barst Robyn J; Fleming Thomas R; Frost Adaani E; Engel Peter J; Kramer Mordechai R; Burgess Gary; Collings Lorraine; Cossons Nandini; Sitbon Olivier; Badesch David B;
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Annals of internal medicine 2008;149(8):521-30.
2008: Ogawa Aiko; Firth Amy L; Yao Weijuan; Rubin Lewis J; Yuan Jason X-J
Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells.
American journal of physiology. Lung cellular and molecular physiology 2008;295(4):L648-57.
2008: Voswinckel Robert; Reichenberger Frank; Enke Beate; Kreckel Andre; Krick Stefanie; Gall Henning; Schermuly Ralph Theo; Grimminger Friedrich; Rubin Lewis J; Olschewski Horst; Seeger Werner; Ghofrani Hossein A
Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
Pulmonary pharmacology & therapeutics 2008;21(5):824-32.
2008: Benza Raymond L; Barst Robyn J; Galie Nazzareno; Frost Adaani; Girgis Reda E; Highland Kristin B; Strange Charlie; Black Carol M; Badesch David B; Rubin Lewis; Fleming Thomas R; Naeije Robert
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.
Chest 2008;134(4):775-82.
2008: Galiè N; Rubin Lj; Hoeper Mm; Jansa P; Al-Hiti H; Meyer Gmb; Chiossi E; Kusic-Pajic A; Simonneau G
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Lancet 2008;371(9630):2093-100.
2008: Rubin Lewis J
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
American journal of respiratory and critical care medicine 2008;177(12):1300-1.
2008: Distler Oliver; Behrens Frank; Pittrow David; Huscher Doerte; Denton Christopher P; Foeldvari Ivan; Humbert Marc; Matucci-Cerinic Marco; Nash Peter; Opitz Christian F; Rubin Lewis J; Seibold James R; Furst Daniel E;
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
Arthritis and rheumatism 2008;59(6):867-75.
2008: Galiè Nazzareno; Olschewski Horst; Oudiz Ronald J; Torres Fernando; Frost Adaani; Ghofrani Hossein A; Badesch David B; McGoon Michael D; McLaughlin Vallerie V; Roecker Ellen B; Gerber Michael J; Dufton Christopher; Wiens Brian L; Rubin Lewis J;
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Circulation 2008;117(23):3010-9.
2008: Chin Kelly M; Rubin Lewis J
Pulmonary arterial hypertension.
Journal of the American College of Cardiology 2008;51(16):1527-38.
2008: Rubin Lewis J
Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future.
Rheumatic diseases clinics of North America 2008;34(1):191-7; viii.
2008: Croom Katherine F; Curran Monique P
Sildenafil: a review of its use in pulmonary arterial hypertension.
Drugs 2008;68(3):383-97.
2007: Badesch David B; Hill Nicholas S; Burgess Gary; Rubin Lewis J; Barst Robyn J; Galiè Nazzareno; Simonneau Gerald;
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
The Journal of rheumatology 2007;34(12):2417-22.
2007: Chin Kelly M; Channick Richard N; Kim Nick H; Rubin Lewis J
Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
Chest 2007;132(3):786-92.
2007: Badesch David B; Abman Steven H; Simonneau Gerald; Rubin Lewis J; McLaughlin Vallerie V
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
Chest 2007;131(6):1917-28.
2007: Anthi Anastasia; Machado Roberto F; Jison Maria L; Taveira-Dasilva Angelo M; Rubin Lewis J; Hunter Lori; Hunter Christian J; Coles Wynona; Nichols James; Avila Nilo A; Sachdev Vandana; Chen Clara C; Gladwin Mark T
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.
American journal of respiratory and critical care medicine 2007;175(12):1272-9.
2007: Zhang Shen; Dong Hui; Rubin Lewis J; Yuan Jason X-J
Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
American journal of physiology. Cell physiology 2007;292(6):C2297-305.
2007: Remillard Carmelle V; Tigno Donna D; Platoshyn Oleksandr; Burg Elyssa D; Brevnova Elena E; Conger Diane; Nicholson Ann; Rana Brinda K; Channick Richard N; Rubin Lewis J; O'connor Daniel T; Yuan Jason X-J
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.
American journal of physiology. Cell physiology 2007;292(5):C1837-53.
2007: Buch M H; Denton C P; Furst D E; Guillevin L; Rubin L J; Wells A U; Matucci-Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black C M; Seibold J R
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.
Annals of the rheumatic diseases 2007;66(2):169-73.
2007: Rubin Lewis J; Black Carol M; Denton Christopher P; Seibold James R
Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease.
Arthritis research & therapy 2007;9 Suppl 2():S10.
2006: Hoeper Marius M; Lee Stephen H; Voswinckel Robert; Palazzini Massimiliano; Jais Xavier; Marinelli Alessandro; Barst Robyn J; Ghofrani Hossein A; Jing Zhi-Cheng; Opitz Christian; Seyfarth Hans-Juergen; Halank Michael; McLaughlin Vallerie; Oudiz Ronald J; Ewert Ralf; Wilkens Heinrike; Kluge Stefan; Bremer Hinrich-Cordt; Baroke Eva; Rubin Lewis J
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers.
Journal of the American College of Cardiology 2006;48(12):2546-52.
2006: Chin Kelly M; Channick Richard N; Rubin Lewis J
Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
Chest 2006;130(6):1657-63.
2006: McLaughlin Vallerie V; Oudiz Ronald J; Frost Adaani; Tapson Victor F; Murali Srinivas; Channick Richard N; Badesch David B; Barst Robyn J; Hsu Henry H; Rubin Lewis J
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
American journal of respiratory and critical care medicine 2006;174(11):1257-63.
2006: Distler O; Behrens F; Huscher D; Foeldvari I; Zink A; Nash P; Denton C P; Humbert M; Matucci-Cerinic M; Seibold J; Rubin L; Furst D E
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis.
Rheumatology (Oxford, England) 2006;45(12):1455-7.
2006: Barst R J; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin L J
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2006;28(6):1195-203.
2006: Voelkel Norbert F; Quaife Robert A; Leinwand Leslie A; Barst Robyn J; McGoon Michael D; Meldrum Daniel R; Dupuis Jocelyn; Long Carlin S; Rubin Lewis J; Smart Frank W; Suzuki Yuichiro J; Gladwin Mark; Denholm Elizabeth M; Gail Dorothy B;
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.
Circulation 2006;114(17):1883-91.
2006: Voswinckel Robert; Enke Beate; Reichenberger Frank; Kohstall Markus; Kreckel Andree; Krick Stefanie; Gall Henning; Gessler Tobias; Schmehl Thomas; Ghofrani Hossein A; Schermuly Ralph Theo; Grimminger Friedrich; Rubin Lewis J; Seeger Werner; Olschewski Horst
Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
Journal of the American College of Cardiology 2006;48(8):1672-81.
2006: Channick Richard N; Olschewski Horst; Seeger Werner; Staub Ted; Voswinckel Robert; Rubin Lewis J
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Journal of the American College of Cardiology 2006;48(7):1433-7.
2006: Denton C P; Humbert M; Rubin L; Black C M
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Annals of the rheumatic diseases 2006;65(10):1336-40.
2006: Rubin Lewis J
Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?
Circulation 2006;114(13):1350-1.
2006: Peacock Andrew; Simonneau Gérald; Rubin Lewis
Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension.
Proceedings of the American Thoracic Society 2006;3(7):608-14.
2006: Rubin Lewis J; Hoeper Marius M; Klepetko Walter; Galiè Nazzareno; Lang Irene M; Simonneau Gérald
Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses.
Proceedings of the American Thoracic Society 2006;3(7):601-7.
2006: Walker Alexander M; Langleben David; Korelitz James J; Rich Stuart; Rubin Lewis J; Strom Brian L; Gonin René; Keast Susan; Badesch David; Barst Robyn J; Bourge Robert C; Channick Richard; Frost Adaani; Gaine Sean; McGoon Michael; McLaughlin Vallerie; Murali Srinivas; Oudiz Ronald J; Robbins Ivan M; Tapson Victor; Abenhaim Lucien; Constantine Ginger
Temporal trends and drug exposures in pulmonary hypertension: an American experience.
American heart journal 2006;152(3):521-6.
2006: Hoeper Marius M; Mayer Eckhard; Simonneau Gérald; Rubin Lewis J
Chronic thromboembolic pulmonary hypertension.
Circulation 2006;113(16):2011-20.
2006: Hoeper Marius M; Rubin Lewis J
Update in pulmonary hypertension 2005.
American journal of respiratory and critical care medicine 2006;173(5):499-505.
2006: Rubin Lewis J
Pulmonary arterial hypertension.
Proceedings of the American Thoracic Society 2006;3(1):111-5.
2005: Sitbon O; McLaughlin V V; Badesch D B; Barst R J; Black C; Galiè N; Humbert M; Rainisio M; Rubin L J; Simonneau G
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Thorax 2005;60(12):1025-30.
2005: Galiè Nazzareno; Ghofrani Hossein A; Torbicki Adam; Barst Robyn J; Rubin Lewis J; Badesch David; Fleming Thomas; Parpia Tamiza; Burgess Gary; Branzi Angelo; Grimminger Friedrich; Kurzyna Marcin; Simonneau Gérald;
Sildenafil citrate therapy for pulmonary arterial hypertension.
The New England journal of medicine 2005;353(20):2148-57.
2005: Laving Ahmed; Khanna Ajai; Rubin Lewis; Ing Frank; Dohil Ranjan; Lavine Joel E
Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol.
Journal of pediatric gastroenterology and nutrition 2005;41(4):466-8.
2005: Kim Nick H S; Rubin Lewis J
Management following pulmonary thromboendarterectomy: experience versus evidence.
Critical care medicine 2005;33(9):2132-3.
2005: Hsu Henry H; Rubin Lewis J
Iloprost inhalation solution for the treatment of pulmonary arterial hypertension.
Expert opinion on pharmacotherapy 2005;6(11):1921-30.
2005: Lee S H; Rubin L J
Current treatment strategies for pulmonary arterial hypertension.
Journal of internal medicine 2005;258(3):199-215.
2005: Rubin Lewis J; Badesch David B
Evaluation and management of the patient with pulmonary arterial hypertension.
Annals of internal medicine 2005;143(4):282-92.
2005: Galié Nazzareno; Badesch David; Oudiz Ronald; Simonneau Gérald; McGoon Michael D; Keogh Anne M; Frost Adaani E; Zwicke Diane; Naeije Robert; Shapiro Shelley; Olschewski Horst; Rubin Lewis J
Ambrisentan therapy for pulmonary arterial hypertension.
Journal of the American College of Cardiology 2005;46(3):529-35.
2005: Rubin Lewis J; Dufton Christopher; Gerber Michael J
Ambrisentan for pulmonary arterial hypertension.
Future cardiology 2005;1(4):425-32.
2005: Galiè Nazzareno; Torbicki Adam; Barst Robyn; Dartevelle Philippe; Haworth Sheila; Higenbottam Tim; Olschewski Horst; Peacock Andrew; Pietra Giuseppe; Rubin Lewis J; Simonneau Gerald;
[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]
Revista española de cardiología 2005;58(5):523-66.
2005: Rubin Lewis J
Epoprostenol and nesiritide in pulmonary hypertension.
Chest 2005;127(5):1870.
2005: Yuan Jason X-J; Rubin Lewis J
Pathogenesis of pulmonary arterial hypertension: the need for multiple hits.
Circulation 2005;111(5):534-8.
2005: McLaughlin V V; Sitbon O; Badesch D B; Barst R J; Black C; Galiè N; Rainisio M; Simonneau G; Rubin L J
Survival with first-line bosentan in patients with primary pulmonary hypertension.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005;25(2):244-9.
2005: Chin Kelly M; Kim Nick H S; Rubin Lewis J
The right ventricle in pulmonary hypertension.
Coronary artery disease 2005;16(1):13-8.
2004: Galiè Nazzareno; Torbicki Adam; Barst Robyn; Dartevelle Philippe; Haworth Sheila; Higenbottam Tim; Olschewski Horst; Peacock Andrew; Pietra Giuseppe; Rubin Lewis J; Simonneau Gerald; Priori Silvia G; Garcia Maria Angeles Alonso; Blanc Jean-Jacques; Budaj Andrzej; Cowie Martin; Dean Verconcia; Deckers Jaap; Burgos Enrique Fernandez; Lekakis John; Lindahl Bertil; Mazzotta Gianfranco; McGregor Keith; Morais João; Oto Ali; Smiseth Otto A; Barbera Joan Albert; Gibbs Simon; Hoeper Marius; Humbert Marc; Naeije Robert; Pepke-Zaba Joanna;
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
European heart journal 2004;25(24):2243-78.
2004: Kunichika Naomi; Landsberg Judd W; Yu Ying; Kunichika Hideki; Thistlethwaite Patricia A; Rubin Lewis J; Yuan Jason X-J
Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes.
American journal of respiratory and critical care medicine 2004;170(10):1101-7.
2004: Yu Ying; Fantozzi Ivana; Remillard Carmelle V; Landsberg Judd W; Kunichika Naomi; Platoshyn Oleksandr; Tigno Donna D; Thistlethwaite Patricia A; Rubin Lewis J; Yuan Jason X-J
Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(38):13861-6.
2004: Humbert M; Barst R J; Robbins I M; Channick R N; Galiè N; Boonstra A; Rubin L J; Horn E M; Manes A; Simonneau G
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2004;24(3):353-9.
2004: Mandegar Mehran; Fung Yuan-Cheng B; Huang Wei; Remillard Carmelle V; Rubin Lewis J; Yuan Jason X-J
Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension.
Microvascular research 2004;68(2):75-103.
2004: Oudiz Ronald J; Schilz Robert J; Barst Robyn J; Galié Nazzareno; Rich Stuart; Rubin Lewis J; Simonneau Gérald;
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Chest 2004;126(2):420-7.
2004: Rubin Lewis J; Naeije Robert
Sildenafil for enhanced performance at high altitude?
Annals of internal medicine 2004;141(3):233-5.
2004: Rubin Lewis J;
Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Chest 2004;126(1 Suppl):7S-10S.
2004: Rubin Lewis J;
Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Chest 2004;126(1 Suppl):4S-6S.
2004: Elliott C Gregory; Rubin Lewis J
Mars or venus--is sex a risk factor for recurrent venous thromboembolism?
The New England journal of medicine 2004;350(25):2614-6.
2004: Rubin Lewis J; Galiè Nazzareno
Pulmonary arterial hypertension: a look to the future.
Journal of the American College of Cardiology 2004;43(12 Suppl S):89S-90S.
2004: Galiè Nazzareno; Seeger Werner; Naeije Robert; Simonneau Gerald; Rubin Lewis J
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.
Journal of the American College of Cardiology 2004;43(12 Suppl S):81S-88S.
2004: Channick Richard N; Sitbon Olivier; Barst Robyn J; Manes Alessandra; Rubin Lewis J
Endothelin receptor antagonists in pulmonary arterial hypertension.
Journal of the American College of Cardiology 2004;43(12 Suppl S):62S-67S.
2004: Simonneau Gerald; Galiè Nazzareno; Rubin Lewis J; Langleben David; Seeger Werner; Domenighetti Guido; Gibbs Simon; Lebrec Didier; Speich Rudolf; Beghetti Maurice; Rich Stuart; Fishman Alfred
Clinical classification of pulmonary hypertension.
Journal of the American College of Cardiology 2004;43(12 Suppl S):5S-12S.
2004: Bresser P; Fedullo P F; Auger W R; Channick R N; Robbins I M; Kerr K M; Jamieson S W; Rubin L J
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2004;23(4):595-600.
2004: Kim Nick H S; Fesler Pierre; Channick Richard N; Knowlton Kirk U; Ben-Yehuda Ori; Lee Stephen H; Naeije Robert; Rubin Lewis J
Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
Circulation 2004;109(1):18-22.
2003: Kim Nick H; Channick Richard N; Rubin Lewis J
Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension.
Chest 2003;124(4):1612-5.
2003: Bonderman Diana; Turecek Peter L; Jakowitsch Johannes; Weltermann Ansgar; Adlbrecht Christopher; Schneider Barbara; Kneussl Meinhard; Rubin Lewis J; Kyrle Paul A; Klepetko Walter; Maurer Gerald; Lang Irene M
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.
Thrombosis and haemostasis 2003;90(3):372-6.
2003: Zhang Shen; Fantozzi Ivana; Tigno Donna D; Yi Eunhee S; Platoshyn Oleksandr; Thistlethwaite Patricia A; Kriett Jolene M; Yung Gordon; Rubin Lewis J; Yuan Jason X-J
Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells.
American journal of physiology. Lung cellular and molecular physiology 2003;285(3):L740-54.
2003: Sitbon Olivier; Badesch David B; Channick Richard N; Frost Adaani; Robbins Ivan M; Simonneau Gérald; Tapson Victor F; Rubin Lewis J
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Chest 2003;124(1):247-54.
2003: Barst Robyn J; McGoon Michael; McLaughlin Vallerie; Tapson Victor; Rich Stuart; Rubin Lewis; Wasserman Karlman; Oudiz Ronald; Shapiro Shelley; Robbins Ivan M; Channick Richard; Badesch David; Rayburn Barry K; Flinchbaugh Robin; Sigman Jeff; Arneson Carl; Jeffs Roger;
Beraprost therapy for pulmonary arterial hypertension.
Journal of the American College of Cardiology 2003;41(12):2119-25.
2003: Galiè Nazzareno; Hinderliter Alan L; Torbicki Adam; Fourme Thierry; Simonneau Gerald; Pulido Tomas; Espinola-Zavaleta Nilda; Rocchi Guido; Manes Alessandra; Frantz Robert; Kurzyna Marcin; Nagueh Sherif F; Barst Robyn; Channick Richard; Dujardin Karl; Kronenberg Andrew; Leconte Isabelle; Rainisio Maurizio; Rubin Lewis
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Journal of the American College of Cardiology 2003;41(8):1380-6.
2003: Kerr Kim M; Rubin Lewis J
Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
Chest 2003;123(2):319-20.
2003: McLaughlin Vallerie V; Gaine Sean P; Barst Robyn J; Oudiz Ronald J; Bourge Robert C; Frost Adaani; Robbins Ivan M; Tapson Victor F; McGoon Michael D; Badesch David B; Sigman Jeff; Roscigno Robert; Blackburn Shelmer D; Arneson Carl; Rubin Lewis J; Rich Stuart;
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
Journal of cardiovascular pharmacology 2003;41(2):293-9.
2003: Fesler P; Pagnamenta A; Vachiéry J L; Brimioulle S; Abdel Kafi S; Boonstra A; Delcroix M; Channick R N; Rubin L J; Naeije R
Single arterial occlusion to locate resistance in patients with pulmonary hypertension.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2003;21(1):31-6.
2002: Williamson Timothy L; Kim Nick H; Rubin Lewis J
Chronic thromboembolic pulmonary hypertension.
Progress in cardiovascular diseases 2002;45(3):203-12.
2002: Rubin Lewis J
Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.
American journal of respiratory and critical care medicine 2002;166(10):1308-9.
2002: Olschewski Horst; Simonneau Gerald; Galiè Nazzareno; Higenbottam Timothy; Naeije Robert; Rubin Lewis J; Nikkho Sylvia; Speich Rudolf; Hoeper Marius M; Behr Jürgen; Winkler Jörg; Sitbon Olivier; Popov Wladimir; Ghofrani H Ardeschir; Manes Alessandra; Kiely David G; Ewert Ralph; Meyer Andreas; Corris Paul A; Delcroix Marion; Gomez-Sanchez Miguel; Siedentop Harald; Seeger Werner;
Inhaled iloprost for severe pulmonary hypertension.
The New England journal of medicine 2002;347(5):322-9.
2002: Rubin Lewis J; Roux Sébastien
Bosentan: a dual endothelin receptor antagonist.
Expert opinion on investigational drugs 2002;11(7):991-1002.
2002: Hoeper Marius M; Galiè Nazzareno; Simonneau Gerald; Rubin Lewis J
New treatments for pulmonary arterial hypertension.
American journal of respiratory and critical care medicine 2002;165(9):1209-16.
2002: Rubin Lewis J; Badesch David B; Barst Robyn J; Galie Nazzareno; Black Carol M; Keogh Anne; Pulido Tomas; Frost Adaani; Roux Sebastien; Leconte Isabelle; Landzberg Michael; Simonneau Gerald
Bosentan therapy for pulmonary arterial hypertension.
The New England journal of medicine 2002;346(12):896-903.
2002: Simonneau Gerald; Barst Robyn J; Galie Nazzareno; Naeije Robert; Rich Stuart; Bourge Robert C; Keogh Anne; Oudiz Ronald; Frost Adaani; Blackburn Shelmer D; Crow James W; Rubin Lewis J;
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
American journal of respiratory and critical care medicine 2002;165(6):800-4.
2002: Clapp Lucie H; Finney Paul; Turcato Sally; Tran Sandy; Rubin Lewis J; Tinker Andrew
Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.
American journal of respiratory cell and molecular biology 2002;26(2):194-201.
2002: Kim Nick H S; Rubin Lewis J
Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
Journal of cardiovascular pharmacology and therapeutics 2002;7(1):9-19.
2002: Krick Stefanie; Platoshyn Oleksandr; Sweeney Michele; McDaniel Sharon S; Zhang Shen; Rubin Lewis J; Yuan Jason X-J
Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells.
American journal of physiology. Heart and circulatory physiology 2002;282(1):H184-93.
2001: Fedullo P F; Auger W R; Kerr K M; Rubin L J
Chronic thromboembolic pulmonary hypertension.
The New England journal of medicine 2001;345(20):1465-72.
2001: Robbins I M; Barst R J; Rubin L J; Gaine S P; Price P V; Morrow J D; Christman B W
Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension.
Chest 2001;120(5):1639-44.
2001: Channick R N; Simonneau G; Sitbon O; Robbins I M; Frost A; Tapson V F; Badesch D B; Roux S; Rainisio M; Bodin F; Rubin L J
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet 2001;358(9288):1119-23.
2001: Robbins I M; Barst R J; Channick R N; Rubin L J
Pulmonary vasoreactivity in PPH.
Journal of the American College of Cardiology 2001;38(4):1267-8.
2001: Krick S; Platoshyn O; McDaniel S S; Rubin L J; Yuan J X
Augmented K(+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis.
American journal of physiology. Lung cellular and molecular physiology 2001;281(4):L887-94.
2001: Fedullo P F; Auger W R; Channick R N; Kerr K M; Rubin L J
Chronic thromboembolic pulmonary hypertension.
Clinics in chest medicine 2001;22(3):561-81.
2001: Channick R N; Rubin L J
New and experimental therapies for pulmonary hypertension.
Clinics in chest medicine 2001;22(3):539-45.
2001: Yu Y; Platoshyn O; Zhang J; Krick S; Zhao Y; Rubin L J; Rothman A; Yuan J X
c-Jun decreases voltage-gated K(+) channel activity in pulmonary artery smooth muscle cells.
Circulation 2001;104(13):1557-63.
2001: Limsuwan A; Platoshyn O; Yu Y; Rubin L J; Rothman A; Yuan J X
Inhibition of K(+) channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease.
Pediatric research 2001;50(1):23-8.
2001: Rubin L J
Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery.
Critical care medicine 2001;29(5):1086-7.
2001: McDaniel S S; Platoshyn O; Wang J; Yu Y; Sweeney M; Krick S; Rubin L J; Yuan J X
Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction.
American journal of physiology. Lung cellular and molecular physiology 2001;280(5):L870-80.
2001: Platoshyn O; Yu Y; Golovina V A; McDaniel S S; Krick S; Li L; Wang J Y; Rubin L J; Yuan J X
Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes.
American journal of physiology. Lung cellular and molecular physiology 2001;280(4):L801-12.
2001: Bailey C L; Channick R N; Rubin L J
A new era in the treatment of primary pulmonary hypertension.
Heart (British Cardiac Society) 2001;85(3):251-2.
2001: Golovina V A; Platoshyn O; Bailey C L; Wang J; Limsuwan A; Sweeney M; Rubin L J; Yuan J X
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation.
American journal of physiology. Heart and circulatory physiology 2001;280(2):H746-55.
2000: Yung G L; Rubin L J
Approach to pulmonary hypertension.
Current rheumatology reports 2000;2(6):517-23.
2000: Gaine S P; Rubin L J; Kmetzo J J; Palevsky H I; Traill T A
Recreational use of aminorex and pulmonary hypertension.
Chest 2000;118(5):1496-7.
2000: Bailey C L; Channick R N; Auger W R; Fedullo P F; Kerr K M; Yung G L; Rubin L J
"High probability" perfusion lung scans in pulmonary venoocclusive disease.
American journal of respiratory and critical care medicine 2000;162(5):1974-8.
2000: Platoshyn O; Golovina V A; Bailey C L; Limsuwan A; Krick S; Juhaszova M; Seiden J E; Rubin L J; Yuan J X
Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation.
American journal of physiology. Cell physiology 2000;279(5):C1540-9.
2000: Fedullo P F; Rubin L J; Kerr K M; Auger W R; Channick R N
The natural history of acute and chronic thromboembolic disease: the search for the missing link.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2000;15(3):435-7.
2000: Channick R N; Rubin L J
Combination therapy for pulmonary hypertension: a glimpse into the future?
Critical care medicine 2000;28(3):896-7.
2000: Badesch D B; Tapson V F; McGoon M D; Brundage B H; Rubin L J; Wigley F M; Rich S; Barst R J; Barrett P S; Kral K M; Jöbsis M M; Loyd J E; Murali S; Frost A; Girgis R; Bourge R C; Ralph D D; Elliott C G; Hill N S; Langleben D; Schilz R J; McLaughlin V V; Robbins I M; Groves B M; Shapiro S; Medsger T A
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Annals of internal medicine 2000;132(6):425-34.
2000: Rich S; Rubin L; Walker A M; Schneeweiss S; Abenhaim L
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Chest 2000;117(3):870-4.
2000: Lilienfeld D E; Rubin L J
Mortality from primary pulmonary hypertension in the United States, 1979-1996.
Chest 2000;117(3):796-800.
2000: Robbins I M; Gaine S P; Schilz R; Tapson V F; Rubin L J; Loyd J E
Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
Chest 2000;117(1):14-8.
1999: Bakst A E; Gaine S P; Rubin L J
Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
Chest 1999;116(4):1127-9.
1999: Soriano C M; Gaine S P; Conte J V; Fairman R P; White C; Rubin L J
Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction.
Chest 1999;116(2):564-6.
1999: Kuo P C; Plotkin J S; Gaine S; Schroeder R A; Rustgi V K; Rubin L J; Johnson L B
Portopulmonary hypertension and the liver transplant candidate.
Transplantation 1999;67(8):1087-93.
1999: Rubin L J
Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension.
Pediatric pulmonology. Supplement 1999;18():194-7.
1998: Yuan J X; Aldinger A M; Juhaszova M; Wang J; Conte J V; Gaine S P; Orens J B; Rubin L J
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.
Circulation 1998;98(14):1400-6.
1998: Gilbert T B; Gaine S P; Rubin L J; Sequeira A J
Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy.
World journal of surgery 1998;22(10):1029-32; discussion 1033.
1998: Gaine S P; Rubin L J
Primary pulmonary hypertension.
Lancet 1998;352(9129):719-25.
1998: Conte J V; Gaine S P; Orens J B; Harris T; Rubin L J
The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1998;17(7):679-85.
1998: Wang J; Juhaszova M; Conte J V; Gaine S P; Rubin L J; Yuan J X
Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells.
Lancet 1998;352(9124):290.
1998: Yuan X J; Wang J; Juhaszova M; Golovina V A; Rubin L J
Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells.
The American journal of physiology 1998;274(4 Pt 1):L621-35.
1998: Reeves J T; Rubin L J
The pulmonary circulation: snapshots of progress.
American journal of respiratory and critical care medicine 1998;157(4 Pt 2):S101-8.
1998: Gaine S P; Rubin L J
Medical and surgical treatment options for pulmonary hypertension.
The American journal of the medical sciences 1998;315(3):179-84.
1998: Yuan X J; Wang J; Juhaszova M; Gaine S P; Rubin L J
Attenuated K+ channel gene transcription in primary pulmonary hypertension.
Lancet 1998;351(9104):726-7.
1998: Plotkin J S; Kuo P C; Rubin L J; Gaine S; Howell C D; Laurin J; Njoku M J; Lim J W; Johnson L B
Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.
Transplantation 1998;65(4):457-9.
1998: Zhao Y J; Wang J; Rubin L J; Yuan X J
Roles of K+ and Cl- channels in cAMP-induced pulmonary vasodilation.
Experimental lung research 1998;24(1):71-83.
1998: Lippert J L; White C S; Cameron E W; Sun C C; Liang X; Rubin L J
Pulmonary capillary hemangiomatosis: radiographic appearance.
Journal of thoracic imaging 1998;13(1):49-51.
1997: Wang J; Juhaszova M; Rubin L J; Yuan X J
Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells.
The Journal of clinical investigation 1997;100(9):2347-53.
1997: Kuo P C; Plotkin J S; Johnson L B; Howell C D; Laurin J M; Bartlett S T; Rubin L J
Distinctive clinical features of portopulmonary hypertension.
Chest 1997;112(4):980-6.
1997: McCann U D; Seiden L S; Rubin L J; Ricaurte G A
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
JAMA : the journal of the American Medical Association 1997;278(8):666-72.
1997: Hinderliter A L; Willis P W; Barst R J; Rich S; Rubin L J; Badesch D B; Groves B M; McGoon M D; Tapson V F; Bourge R C; Brundage B H; Koerner S K; Langleben D; Keller C A; Murali S; Uretsky B F; Koch G; Li S; Clayton L M; Jöbsis M M; Blackburn S D; Crow J W; Long W A
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.
Circulation 1997;95(6):1479-86.
1997: Zhao Y J; Wang J; Rubin L J; Yuan X J
Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery.
The American journal of physiology 1997;272(2 Pt 2):H904-12.
1997: Kuo P C; Johnson L B; Plotkin J S; Howell C D; Bartlett S T; Rubin L J
Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.
Transplantation 1997;63(4):604-6.
1997: Yuan X J; Bright R T; Aldinger A M; Rubin L J
Nitric oxide inhibits serotonin-induced calcium release in pulmonary artery smooth muscle cells.
The American journal of physiology 1997;272(1 Pt 1):L44-50.
1997: Rubin L J
Primary pulmonary hypertension.
The New England journal of medicine 1997;336(2):111-7.
1996: Zhao Y J; Wang J; Tod M L; Rubin L J; Yuan X J
Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors.
Journal of applied physiology (Bethesda, Md. : 1985) 1996;81(6):2595-603.
1996: Yuan X J; Tod M L; Rubin L J; Blaustein M P
NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(19):10489-94.
1996: Rubin L J
The renin-angiotensin system and the "lesser circulation". A role in cor pulmonale?
Chest 1996;110(3):584-5.
1996: Barst R J; Rubin L J; Long W A; McGoon M D; Rich S; Badesch D B; Groves B M; Tapson V F; Bourge R C; Brundage B H
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.
The New England journal of medicine 1996;334(5):296-302.
1996: Yuan X J; Sugiyama T; Goldman W F; Rubin L J; Blaustein M P
A mitochondrial uncoupler increases KCa currents but decreases KV currents in pulmonary artery myocytes.
The American journal of physiology 1996;270(1 Pt 1):C321-31.
1995: Yuan X J; Tod M L; Rubin L J; Blaustein M P
Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells.
Experimental physiology 1995;80(5):803-13.
1995: Bright R T; Salvaterra C G; Rubin L J; Yuan X J
Inhibition of glycolysis by 2-DG increases [Ca2+]i in pulmonary arterial smooth muscle cells.
The American journal of physiology 1995;269(2 Pt 1):L203-8.
1995: Yuan X J; Tod M L; Rubin L J; Blaustein M P
Inhibition of cytochrome P-450 reduces voltage-gated K+ currents in pulmonary arterial myocytes.
The American journal of physiology 1995;268(1 Pt 1):C259-70.
1995: Rubin L J
Pathology and pathophysiology of primary pulmonary hypertension.
The American journal of cardiology 1995;75(3):51A-54A.
1994: Barst R J; Rubin L J; McGoon M D; Caldwell E J; Long W A; Levy P S
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
Annals of internal medicine 1994;121(6):409-15.
1994: Yuan X J; Tod M L; Rubin L J; Blaustein M P
Deoxyglucose and reduced glutathione mimic effects of hypoxia on K+ and Ca2+ conductances in pulmonary artery cells.
The American journal of physiology 1994;267(1 Pt 1):L52-63.
1993: Salvaterra C G; Rubin L J
Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease.
The American review of respiratory disease 1993;148(5):1414-7.
1993: Rubin L J
Primary pulmonary hypertension.
Chest 1993;104(1):236-50.
1993: Anderson D E; Yuan X J; Tseng C M; Rubin L J; Rosen G M; Tod M L
Nitrone spin-traps block calcium channels and induce pulmonary artery relaxation independent of free radicals.
Biochemical and biophysical research communications 1993;193(3):878-85.
1993: Tseng C M; Goodman L W; Rubin L J; Tod M L
NG-monomethyl-L-arginine paradoxically relaxes preconstricted canine intrapulmonary arteries.
Journal of applied physiology (Bethesda, Md. : 1985) 1993;74(2):549-58.
1993: Yuan X J; Goldman W F; Tod M L; Rubin L J; Blaustein M P
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes.
The American journal of physiology 1993;264(2 Pt 1):L116-23.
1993: Yuan X J; Goldman W F; Tod M L; Rubin L J; Blaustein M P
Ionic currents in rat pulmonary and mesenteric arterial myocytes in primary culture and subculture.
The American journal of physiology 1993;264(2 Pt 1):L107-15.
1992: Tod M L; Rubin L J
Pulmonary vascular responses to thromboxane and prostacyclin.
Journal of applied physiology (Bethesda, Md. : 1985) 1992;73(6):2717-9.
1992: Goyal R; White C S; Templeton P A; Britt E J; Rubin L J
High attenuation mucous plugs in allergic bronchopulmonary aspergillosis: CT appearance.
Journal of computer assisted tomography 1992;16(4):649-50.
1992: Tod M L; Yoshimura K; Rubin L J
Ontogeny of neonatal pulmonary vascular pressure-flow relationships.
The American journal of physiology 1992;262(3 Pt 2):H684-90.
1992: Rubin L J
Primary pulmonary hypertension. Practical therapeutic recommendations.
Drugs 1992;43(1):37-43.
1991: Nall K C; Rubin L J; Lipskind S; Sennesh J D
Reversible pulmonary hypertension associated with anorexigen use.
The American journal of medicine 1991;91(1):97-9.
1991: Tod M L; Yoshimura K; Rubin L J
Indomethacin prevents ventilation-induced decreases in pulmonary vascular resistance of the middle region in fetal lambs.
Pediatric research 1991;29(5):449-54.
1991: Tod M L; Yoshimura K; Rubin L J
Pulmonary vascular distensibility of arterial, middle, and venous regions in newborn lambs.
Journal of applied physiology (Bethesda, Md. : 1985) 1991;70(3):1315-22.
1991: Rubin L J
New concepts in the treatment of primary pulmonary hypertension.
Maryland medical journal (Baltimore, Md. : 1985) 1991;40(3):209-11.
1990: Martin M A; Hebden J N; Bustamante C I; Rubin L J
Group A streptococcal bacteremias associated with intravascular catheters.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1990;11(10):542-4.
1990: Rubin L J; Tod M L; Yoshimura K
Effects of nitrendipine and hypoxia on pulmonary vascular resistance in experimental emphysema.
The American review of respiratory disease 1990;142(3):625-30.
1990: Yuan X J; Tod M L; Rubin L J; Blaustein M P
Contrasting effects of hypoxia on tension in rat pulmonary and mesenteric arteries.
The American journal of physiology 1990;259(2 Pt 2):H281-9.
1990: Rubin L J; Mendoza J; Hood M; McGoon M; Barst R; Williams W B; Diehl J H; Crow J; Long W
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
Annals of internal medicine 1990;112(7):485-91.
1989: Weir E K; Rubin L J; Ayres S M; Bergofsky E H; Brundage B H; Detre K M; Elliott C G; Fishman A P; Goldring R M; Groves B M
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.
The American review of respiratory disease 1989;140(6):1623-30.
1989: Yoshimura K; Tod M L; Pier K G; Rubin L J
Effects of a thromboxane A2 analogue and prostacyclin on lung fluid balance in newborn lambs.
Circulation research 1989;65(5):1409-16.
1989: Rubin L J
Approach to the diagnosis and treatment of pulmonary hypertension.
Chest 1989;96(3):659-64.
1989: Salvaterra C G; Rubin L J; Schaeffer J; Blaustein M P
The influence of the transmembrane sodium gradient on the responses of pulmonary arteries to decreases in oxygen tension.
The American review of respiratory disease 1989;139(4):933-9.
1989: Yoshimura K; Tod M L; Pier K G; Rubin L J
Role of venoconstriction in thromboxane-induced pulmonary hypertension and edema in lambs.
Journal of applied physiology (Bethesda, Md. : 1985) 1989;66(2):929-35.
1988: Silverman H J; Abrams J; Rubin L J
Effects of interleukin-2 on oxygen delivery and consumption in patients with advanced malignancy.
Chest 1988;94(4):816-21.
1988: Rubin L J
Primary pulmonary hypertension.
Chest 1988;93(4):894-5.
1987: Rubin L J; Windberg P; Taylor W; Heatfield B
Pulmonary vascular structural and functional changes in papain-induced emphysema in dogs.
The American review of respiratory disease 1987;136(3):704-9.
1987: Long W A; Rubin L J
Prostacyclin and PGE1 treatment of pulmonary hypertension.
The American review of respiratory disease 1987;136(3):773-6.
1987: Johnson R A; Rubin L J
Noninvasive evaluation of right ventricular function.
Clinics in chest medicine 1987;8(1):65-80.
1987: Rubin L J
Vasodilators and pulmonary hypertension: where do we go from here?
The American review of respiratory disease 1987;135(2):287.
1986: Peil M L; Rubin L J
Oxygen therapy titrated to raise mixed venous oxygen content in COPD.
Chest 1986;89(3):343-7.
1985: Groves B M; Rubin L J; Frosolono M F; Cato A E; Reeves J T
A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension.
American heart journal 1985;110(6):1200-4.
1985: Rubin L J
Pulmonary thromboembolic disease--diagnosis, management and prevention.
The American journal of the medical sciences 1985;290(4):167-77.
1985: Rubin L J
Calcium channel blockers in primary pulmonary hypertension.
Chest 1985;88(4 Suppl):257S-260S.
1984: Hunt J M; Chappell T R; Henrich W L; Rubin L J
Gas exchange during dialysis. Contrasting mechanisms contributing to comparable alterations with acetate and bicarbonate buffers.
The American journal of medicine 1984;77(2):255-60.
1983: Miller M J; Chappell T R; Cook W; De Olazabal J R; Rubin L J
Effects of oral hydralazine on gas exchange in patients with cor pulmonale.
The American journal of medicine 1983;75(6):937-42.
1983: Rubin L J; Nicod P; Hillis L D; Firth B G
Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation.
Annals of internal medicine 1983;99(4):433-8.
1983: Henrich W L; Woodard T D; Meyer B D; Chappell T R; Rubin L J
High sodium bicarbonate and acetate hemodialysis: double-blind crossover comparison of hemodynamic and ventilatory effects.
Kidney international 1983;24(2):240-5.
1983: Chappell T R; Rubin L J; Markham R V; Firth B G
Independence of oxygen consumption and systemic oxygen transport in patients with either stable pulmonary hypertension or refractory left ventricular failure.
The American review of respiratory disease 1983;128(1):30-3.
1983: Cohen M D; Rubin L J; Taylor W E; Cuthbert J A
Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension.
Hepatology (Baltimore, Md.) 1983;3(4):588-92.
1983: Rubin L J
Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
Clinics in chest medicine 1983;4(2):309-19.
1982: Rubin L J; Groves B M; Reeves J T; Frosolono M; Handel F; Cato A E
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
Circulation 1982;66(2):334-8.
1982: Rubin L J; Handel F; Peter R H
The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
Circulation 1982;65(7):1369-73.
1981: Rubin L J; Peter R H
Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale.
The American journal of cardiology 1981;47(1):116-22.
1980: Rubin L J; Peter R H
Primary pulmonary hypertension: new approaches to therapy.
American heart journal 1980;100(5):757-9.
1980: Rubin L J; Peter R H
Oral hydralazine therapy for primary pulmonary hypertension.
The New England journal of medicine 1980;302(2):69-73.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Lewis Rubin

Research Profile (preview)

Disorders

Anatomy

Chemicals & Drugs

Physiology

Concepts & Ideas

Living Beings

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Lewis Rubin (preview)

All Publications